Development of new indoleamide chemosensitizer drugs by targeting nucleotide excision repair mechanism to enhance the efficiency of platinum-based chemotherapy agents on cancer treatment.
This project proposal aimed to reduce of activity of xeroderma pigmentosum complementation group A (XPA) protein which is the most important NER factor, has function at only the pathway and provides regulating of NER by circadian rhythm. For that purpose, lead molecules will design with in silico method and NER inhibitor candidates will synthesis. The effect of candidate inhibitors on NER pathway will determine with in vitro, ex vivo, and in vivo animal experiments. Toxicity tests will perform on effective molecules. At the end of the project, it is aimed to discover a new drug which enhances the efficiency of platinum-based agents.
Project Manager: Muhammet Karaman, Ph.D.
Funding Agency: Health Institutes of Turkey (TÜSEB)
Grant Type: Innovative Drug R&D
Total Cost: 1.482.303,81 ₺
Start/End: 2021/
Synthesis of Schiff Base Derivatives and detection of effect on Pentose Phosphate Pathway.
Cancer is one of the most common health problems worldwide. Although different methods are used for cancer treatment, chemotherapy is the method most frequently referred. Because it threatens tumor types from different tissues and organs due to systemic therapy. Cisplatin is the most commonly used chemotherapeutic agent. Differently, from cisplatin, many chemotherapeutic agents are used either alone or in combination with cisplatin. The pentose phosphate pathway (PPP) is an important target for cancer treatment due to it plays a key role in biosynthesis and DNA synthesis which is the main target for cisplatin. Inhibition of the activity of glucose-6-phosphate dehydrogenase which is the first checkpoint enzyme for the pathway cause slow down or destroys the growth of cancer cells. In this project proposal, in order to inhibit G6PD enzyme activity, novel Schiff base derivatives will be synthesized and then, their effect on G6PD enzyme activity will be determined.
Project Manager: Muhammet Karaman, Ph.D.
Funding Agency: The Scientific and Technological Research Council of Turkey (TÜBİTAK) and Kilis 7 Aralik University, Scientific Research Unit (BAP).
Grant Type: Innovative Drug R&D
Total Cost: 45.000,00 ₺ (TÜBİTAK) 22.000,00 ₺ (BAP)
Start/End: 2020/
